HONG KONG, March 19, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that shareholders have approved all five resolutions at the company’s 2026 Annual General Meeting, providing full authorization for an overhaul of its share capital structure, the introduction of high‑vote Class B shares, a targeted share exchange with a major shareholder, and a large‑scale share consolidation. Authorised Share Capital Changes Shareholders resolved b ...

摘要 ： 《十五五规划纲要（草案）》首次将类器官与器官芯片技术纳入国家战略科技攻关，预示其将成 为生物医药发展新质生产力的关键。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 2026年3月12日，十四届全国人大四次会议表决通过关于国民经济和社会发展第十五个五年 规划纲要的决议。 在这份关系未来五年国家发展方向的纲领性文件中， 类器官与器官芯片技 术首次被明确写入国家战略科技攻关任务 ，标志着我国对新一代人类仿生模型技术的重视进入 全新阶段。 在十五五规划纲要《第三篇 加快高水平科技自立自强 引领发展新质生产力》中，明确提出了 " 攻关人工生命体系合成、 类器官与器官芯片 、器官制造、生物结构与功能成像等技术" 。 这是类器官与器官芯片首次出现在国家五年规划纲要中，意味着该技术已从科研探索阶段正式 上升为国家战略科技力量的重要组成部分。 | 转 载 ： 须 本 号 授 权 ， 请 联 系 主 编 | 来 源 ： 仪 器 信 息 网 | 作 者 ： 陌 上 茴 | 责 编 ： 安 安 | 视 觉 ： 长 艳 柱 子 | | 专栏8 前沿科 ...

As filed with the U.S. Securities and Exchange Commission on March 10, 2026 Registration No. 333-293120 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________ Pono Capital Four, Inc. (Exact name of registrant as specified in its charter) ____________________ Cayman Islands 6770 98-1907673 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classifi ...

As filed with the U.S. Securities and Exchange Commission on March 3, 2026 Registration No. 333-293120 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________ Pono Capital Four, Inc. (Exact name of registrant as specified in its charter) ____________________ Cayman Islands 6770 98-1907673 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classific ...

Core Insights - Advanced Biomed Inc. has entered into a clinical research collaboration with Chi-Mei Medical Center to conduct a 120-case feasibility study on its A+PerfusC platform, aimed at evaluating predictive accuracy in oncology treatment selection [1][2]. Group 1: Study Details - The feasibility study is a non-interventional clinical research project approved by the Institutional Review Board, with case collection starting in early February 2026 and full completion targeted by year-end 2026 [2]. - Interim comparative data from the study is expected in May–June 2026, focusing on the correlation between drug sensitivity results from the A+PerfusC platform and actual patient clinical outcomes [2][4]. Group 2: Technological Advantages - The A+PerfusC platform utilizes label-free microfluidic technology to isolate high-viability circulating tumor cells, enabling automated 3D culture arrays for parallel drug testing, which addresses limitations of traditional 2D models and xenograft animal models [3][4]. - This innovative approach aims to reduce the time to evidence-based treatment decisions and minimize patient exposure to ineffective therapies [3]. Group 3: Collaboration and Future Plans - The collaboration with Chi-Mei Medical Center will involve joint clinical research and commercial development, with both parties sharing rights to project-related intellectual property and research outcomes [5]. - The results from the feasibility study are expected to inform the design of larger clinical validation studies and support the A+PerfusC platform's use as a predictive tool for treatment response [4]. Group 4: Company Overview - Advanced Biomed Inc. specializes in innovative biomedical technologies for cancer detection and precision medicine, operating through a subsidiary in Taiwan [6][7]. - The company has developed a proprietary microfluidic platform for advanced circulating tumor cell detection, with plans for regulatory clearances in Taiwan and future global expansion [7].

Core Viewpoint - Standard BioTools Inc. has completed the sale of SomaLogic to Illumina for $350 million upfront, with potential total proceeds of up to $425 million, marking a significant step in the company's strategic transformation and positioning for future growth [1][2]. Financial Details - The company received $350 million in upfront cash and is eligible for up to $75 million in near-term earnout payments based on performance metrics for 2025 and 2026 [2][12]. - Following the transaction, Standard BioTools estimates a cash and cash equivalents balance of approximately $550 million, which will support its inorganic growth strategy [4]. Strategic Implications - The sale is viewed as a major milestone in the company's strategic transformation, allowing it to pursue disciplined mergers and acquisitions to accelerate growth [2]. - Standard BioTools will receive a 2% royalty on net revenues from SOMAmer-based NGS library preparation kits for a duration of 10 years, along with a co-exclusive license for related intellectual property [3]. Operational Outlook - The company is on track to achieve positive adjusted EBITDA by 2026, indicating a focus on improving operational performance post-transaction [1].

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Chengdu Zenitar Biomedical Technology Co., Ltd. 成都賾靈生物醫藥科技股份有限公司 (the "Company") (A joint stock company incorporated in the People's Republic of C ...

Core Insights - Biomerica, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has set a national Medicare payment rate of $300 for its inFoods® IBS test, effective January 1, 2026, under the Clinical Laboratory Fee Schedule (CLFS) [1][9] - The establishment of a dedicated CPT® Proprietary Laboratory Analyses (PLA) code for inFoods® IBS, effective October 1, 2025, enhances the test's market position and patient access [2] Commercial Milestone - The $300 payment rate from CMS provides a foundation for negotiations with private insurers, as CMS is the largest payer in the U.S. healthcare system, accounting for approximately 21% of total healthcare expenditure [3][9] - The CEO of Biomerica emphasized that the pricing determination is a significant milestone for both the company and patients suffering from IBS, positioning the company for commercial growth in 2026 and beyond [4] Market Need - Irritable bowel syndrome (IBS) affects about 10% to 15% of adults in the U.S., translating to over 30 million potential patients, highlighting a significant unmet medical need [4] - Current treatment options for IBS often provide inconsistent relief and may involve side effects, with no FDA-approved drugs for the IBS-M subtype, which represents about one-third of the IBS market [4] Product Efficacy - The inFoods® IBS test utilizes a personalized diagnostic approach to identify food triggers for IBS symptoms, allowing for targeted dietary recommendations [5] - Clinical trials demonstrated that 59.6% of patients who eliminated identified trigger foods met the FDA-standard target for abdominal pain reduction, compared to 42.2% in the control group [6] - Notable efficacy was observed in difficult-to-treat populations, with 67.1% of IBS-C patients and 66% of IBS-M patients achieving FDA-target pain reduction [7] Strategic Positioning - The combination of clinical evidence, a dedicated PLA code, and a national CLFS price represents a pivotal moment for inFoods® IBS [8] - The company plans to work with Medicare Administrative Contractors to secure coverage for the inFoods® IBS test and leverage the established pricing to negotiate with private insurers [10] Value Proposition - The CMS pricing announcement enhances Biomerica's market opportunity by providing a differentiated offering, a large patient population, a personalized medicine approach, and platform potential for additional gastrointestinal conditions [11]

Core Viewpoint - Ping An Biomedical Co., Ltd. has received a deficiency letter from Nasdaq regarding its minimum bid price requirement, indicating potential risks to its continued listing status [2][3]. Group 1: Compliance and Listing Status - The company was notified by Nasdaq that it no longer meets the minimum bid price requirement of $1 per share based on its closing bid price from October 10, 2025, to November 20, 2025 [2]. - Nasdaq has granted the company a compliance period of 180 calendar days, until May 25, 2026, to regain compliance with the listing requirement [3]. - If the company fails to regain compliance within the initial compliance period, it may be eligible for an additional 180 days, provided it meets other listing standards and notifies Nasdaq of its intention to cure the deficiency [3]. Group 2: Company's Response and Future Plans - The company is currently evaluating options to regain compliance and is committed to making reasonable efforts to meet Nasdaq's continued listing requirements [4]. - There is no assurance that the company will successfully regain compliance with the minimum bid price rule or other Nasdaq requirements [4]. Group 3: Company Overview - Ping An Biomedical Co., Ltd. is a one-stop supply chain management service provider in the apparel industry and focuses on innovative solutions in healthcare and biomedical technology [5].

Core Insights - Advanced Biomed Inc. has launched the A+PerfusC system, a compact 3D cell culture incubator designed to replicate human physiological conditions in vitro [1][2] - The A+PerfusC platform integrates automated perfusion with environmental control, allowing for up to 12 days of continuous, hands-free culture, which enhances cell viability and drug response predictability [2][5] - The global 3D cell culture market is projected to grow from USD 2.32 billion in 2025 to over USD 4.71 billion by 2030, with a compound annual growth rate of over 15.6% [4] Company Overview - Advanced Biomed Inc. specializes in innovative biomedical technologies for cancer detection and precision medicine, operating through subsidiaries in Taiwan, Hong Kong, and Mainland China [9][10] - The company has developed a proprietary microfluidic platform for advanced circulating tumor cell detection, with regulatory clearances in progress in China and plans for global expansion [10] Product Features - The A+PerfusC system supports up to 8 independent channels per plate, allowing for 600 tumor spheroids per row and a total of 4,800 tumor spheroids per plate [8] - The system is designed for easy transfer into 96 or 384 well plates for high-throughput drug screening and can be mounted on microscopy platforms [8] Future Plans - The company plans to scale up the A+PerfusC system for high-throughput use and integrate imaging with AI-driven analytics to enhance tumor profiling and personalized treatment development [5]